Table 3.
Effect of intravenous NaNO2 on combined nitrate and nitrite (NOx) and cGMP
| Baseline | Infusion | Post-infusion | p RM ANOVA (one-way) | ||
|---|---|---|---|---|---|
| 60 min | 120 min | 180 min | |||
| P-NOx (μmol/l) | |||||
| Placebo | 17 (13;21) | 25 (19;31)* | 31 (24;38)* | 29 (22;35)* | <.001 |
| Allopurinol | 17 (14;23) | 24 (19;30)* | 32 (26;36)* | 30 (26;32)* | <.001 |
| Enalapril | 15 (12;19) | 24 (21;31)* | 29 (26;32)* | 27 (24;31)* | <.001 |
| Acetazolamide | 17 (13;19) | 24 (21;31)* | 30 (27;35)* | 27 (23;32)* | <.001 |
| pinteraction (pretreatment x time) | .742 | ||||
| U-NOx (μmol/min) | |||||
| Placebo | 0.52 (0.37;0.69) | 0.72 (0.52;0.79)* | 0.94 (0.88;1.09)* | 0.95 (0.83;1.21)* | <.001 |
| Allopurinol | 0.60 (0.42;0.88) | 0.79 (0.65;0.98)* | 0.99 (0.87;1.23)* | 1.07 (0.90;1.18)* | <.001 |
| Enalapril | 0.57 (0.44;0.78) | 0.69 (0.59;0.97)* | 0.99 (0.87;1.22)* | 0.94 (0.80;1.31)* | <.001 |
| Acetazolamide | 0.49 (0.45;0.54) | 0.63 (0.59;0.67)* | 0.98 (0.86;1.05)* | 0.94 (0.85;1.06)* | <.001 |
| pinteraction (pretreatment x time) | .677 | ||||
| P-cGMP (pmol/ml) | |||||
| Placebo | 88 [78;98] | 93 [83;104] | 87 [78;95] | .310 | |
| Allopurinol | 91 [83;100] | 87 [77;98] | 88 [77;98] | .597 | |
| Enalapril | 82 [71;92] | 85 [74;96] | 93 [75;110] | .102 | |
| Acetazolamide | 90 [78;101] | 84 [74;93] | 84 [74;94] | .088 | |
| pinteraction (pretreatment x time) | .111 | ||||
| U-cGMP (pmol/min) | |||||
| Placebo | 425 (356;530) | 426 (371;561) | 414 (341;515) | 321 (235;343)* | <.001 |
| Allopurinol | 487 (388;613) | 453 (353;575) | 461 (376;570) | 367 (287;443)* | <.001 |
| Enalapril | 404 (291;527)† | 425 (329;552) | 409 (309;486) | 284 (243;349)* | <.001 |
| Acetazolamide | 361 (305;484)† | 345 (296;468) | 372 (325;470) | 269 (236;324)* | <.001 |
| pinteraction (pretreatment x time) | .362 | ||||
Effect of intravenous NaNO2 on plasma concentrations (n = 16) and urinary excretion rates (n = 14) of combined nitrate and nitrite (NOx) and guanosine 3′,5′-cyclic monophosphate (cGMP) in healthy subjects after 4 days pretreatment with allopurinol, enalapril, acetazolamide, or placebo. Normal distributed data are presented as means with 95% confidence interval in brackets and non-parametric data as medians with 25th and 75th percentiles in parentheses. Statistics were performed using one-way repeated measures (RM) ANOVA for comparing over time and two-way RM ANOVA with time and pretreatment as within factors to test for interaction. Pairwise comparison where performed using Student’s t-test. P-NOx, U-NOx and U-cGMP were log transformed prior to testing
* p < .05 within group vs. baseline (Bonferroni), † p < .05 vs. placebo at baseline